Lars D. Engstrom

Pfizer

H指数:17

被引数:4,265

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

SOS1抑制剂MRTX0902阻断KRAS激活并在依赖KRAS核苷酸负载的癌症中显示抗肿瘤活性

MOLECULAR CANCER THERAPEUTICS

IF5.5

2024-04-194

OAAI

Sudhakar, Niranjan; Yan, Larry; Qiryaqos, Fadia; Engstrom, Lars D.; Laguer, Jade; Calinisan, Andrew; Hebbert, Allan; Waters, Laura; Moya, Krystal; Bowcut, Vickie; Vegar, Laura; Ketcham, John M.; Ivetac, Anthony; Smith, Christopher R.; Lawson, J. David; Rahbaek, Lisa; Clarine, Jeffrey; Nguyen, Natalie; Saechao, Barbara; Parker, Cody; Elliott, Adam J.; Vanderpool, Darin; He, Leo; Hover, Laura D.; Fernandez-Banet, Julio; Coma, Silvia; Pachter, Jonathan A.; Hallin, Jill; Marx, Matthew A.; Briere, David M.; Christensen, James G.; Olson, Peter; Haling, Jacob; Khare, Shilpi

The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased antitumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-03-133

OAAI

Ketcham, John M.; Harwood, Stephen J.; Aranda, Ruth; Aloiau, Athenea N.; Bobek, Briana M.; Briere, David M.; Burns, Aaron C.; Haatveit, Kersti Caddell; Calinisan, Andrew; Clarine, Jeffery; Elliott, Adam; Engstrom, Lars D.; Gunn, Robin J.; Ivetac, Anthony; Jones, Benjamin; Kuehler, Jon; Lawson, J. David; Nguyen, Natalie; Parker, Cody; Pearson, Kelly E.; Rahbaek, Lisa; Saechao, Barbara; Wang, Xiaolun; Waters, Anna; Waters, Laura; Watkins, Ashlee H.; Olson, Peter; Smith, Christopher R.; Christensen, James G.; Marx, Matthew A.

TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers

MOLECULAR CANCER RESEARCH

IF4.7

2023-05-010

PRE

Identification of mechanism-based combination targets effective with the MTAcooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers

CANCER RESEARCH

IF16.6

2023-04-042

PRE

A novel MTAcooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers

CANCER RESEARCH

IF16.6

2023-04-041

PRE

Inhibition of SOS1 by MRTX0902 augments the antitumor response of the targeted EGFR inhibitor osimertinib in NSCLC

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

一种有效的选择性非共价KRASG12D抑制剂的抗肿瘤功效

NATURE MEDICINE

IF50

2022-10-10207

Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M.; Hargis, Lauren; Engstrom, Lars D.; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; Lawson, J. David; Gunn, Robin J.; Smith, Christopher R.; Thomas, Nicole C.; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon; He, Leo; Fernandez-Banet, Julio; Pavlicek, Adam; Haling, Jacob R.; Rahbaek, Lisa; Marx, Matthew A.; Olson, Peter; Christensen, James G.

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl) phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2022-10-019

PRE

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-01-1876

Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-012

PRE

MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-012

PRE

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-03-15111

The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models

CANCER RESEARCH

IF16.6

2020-08-151

PRE

Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models

CANCER RESEARCH

IF16.6

2020-08-151

PRE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

KRASG12C抑制剂MRTX849为小鼠模型和患者中KRAS突变癌症的治疗易感性提供了见解

CANCER DISCOVERY

IF33.3

2020-01-09702

OAAI

Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M.; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R.; Ballard, Joshua A.; Burkard, Michael R.; Fell, Jay B.; Fischer, John P.; Vigers, Guy P.; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C.; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F., III; Cassidy, Douglas P.; Marx, Matthew A.; Rybkin, Igor I.; Johnson, Melissa L.; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P.; Janne, Pasi A.; Olson, Peter; Christensen, James G.

The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-013

PRE

The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-019

PRE

Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor

CANCER RESEARCH